Folikabi 10 mg/ml oplossing voor injectie/infusie

DRUG3 trials

Sponsors

Amsterdam UMC, Catharina Ziekenhuis Stichting, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Conditions

Borderline resectable pancreatic cancer (BRPC)Pancreatic cancerRectal cancerResectable pancreatic cancer (RPC)

Phase 1

Neoadjuvant Triple Treatment with mFOLFIRINOX, pembrolizumab and SABR in patients with (borderline) resectable pancreatic cancer (PREOPANC-5): a multicenter single arm phase Ib/II trial of the Dutch Pancreatic Cancer Group

RecruitingCTIS2023-508707-20-00

Amsterdam UMCBorderline resectable pancreatic cancer (BRPC), Pancreatic cancer, Resectable pancreatic cancer (RPC)

Start: 2024-09-19Target: 66Updated: 2025-12-15

Phase 2

Personalized dosing of FOLFIRINOX in pancreatic cancer patients: a phase-2 pharmacokinetic, safety and feasibility trial

RecruitingCTIS2024-510576-21-00

Catharina Ziekenhuis StichtingPancreatic cancer

Start: 2024-09-18Target: 100Updated: 2024-07-09

Phase 3

Adjuvant chemotherapy for prevention of recurrence in patients with detectable ctDNA after surgery in high-riskrectal cancer.

Not yet recruitingCTIS2024-517700-12-00

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rectal cancer

Target: 103Updated: 2026-01-20